Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GLs for Proper Use of Anticancer Drugs Presented: Meeting
February 25, 2002
- BUSINESS NEWS IN BRIEF
February 25, 2002
- Treatment GLs for Hyperuricemia, Gout Announced: Society Meeting
February 25, 2002
- WEBSITE NEWS
February 25, 2002
- 700 Renal Transplants Performed in 2001: Meeting
February 25, 2002
- Details of FY2002 NHI Pricing System Reform Approved by Chuikyo
February 25, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 25, 2002
- NHI Pricing System Needs Reform from Mid-, Long-term Perspectives: EAD Director, FPMAJ
February 25, 2002
- Japanese Language Books
February 25, 2002
- LDP Listens to Industry's Views on Pharmaceutical Regulations
February 25, 2002
- Consumers' Interest in Self-medication Increases: PAJ Survey
February 25, 2002
- Reform Should Promote Industry: LDP Diet Member
February 25, 2002
- Matsumotokiyoshi Ties Up with Shimizu Yakuhin
February 25, 2002
- PFSB to Computerize All Administrative Procedures in FY2003
February 25, 2002
- Suzuken: New Blood Pressure Monitors
February 25, 2002
- Medical Institutions Should Join Discussions on Distribution Reform: Mr Matsutani of FJPWA
February 25, 2002
- Bio Media: New Sprayer for Sterilization
February 25, 2002
- Yamanouchi Expects 50% of Its Asian Sales in China
February 25, 2002
- AstraZeneca: Sales Up 8% to US$16,480 Mil.
February 25, 2002
- JPMA to Continue to Demand Better Protection of NDA Dossiers
February 25, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…